PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1

Area of Science:

• Oncology
• Molecular Biology
• Cell Death Signaling

Background:

• Breast cancer recurrence, often incurable, is linked to reduced prostate apoptosis response-4 (PAR-4) levels.
• Prostate apoptosis response-4 (PAR-4) is a tumor suppressor protein crucial for apoptosis.
• Loss of PAR-4 is associated with chemotherapy resistance in triple-negative breast cancer (TNBC).

Purpose of the Study:

• To investigate the role of PAR-4 in chemoresistance and apoptosis in TNBC.
• To elucidate the mechanism by which PAR-4 loss confers resistance to DNA damage-induced apoptosis.
• To identify therapeutic strategies to overcome PAR-4-mediated chemoresistance in TNBC.

Main Methods:

• Utilized triple-negative breast cancer (TNBC) cell lines with varying PAR-4 expression.
• Investigated apoptosis signaling pathways, including caspase-8 activation and inhibitor of apoptosis (IAP) protein levels.
• Employed RNA interference (RNAi) and Smac mimetics (LCL161) to target cIAP1.

Main Results:

• Loss of PAR-4 in TNBC cells prevents DNA damage-induced apoptosis and caspase-8 activation.
• PAR-4 deficiency inhibits the depletion of cellular inhibitor of apoptosis protein 1 (cIAP1) following DNA damage.
• Nuclear translocation of the PAR-4 C-terminal fragment mediates cIAP1 depletion and subsequent caspase-8 activation.
• Targeting cIAP1 with RNAi or Smac mimetics restored chemo-sensitivity and caspase-8 activation in PAR-4 deficient TNBC cells.

Conclusions:

• PAR-4 functions downstream of caspase-8, with its C-terminal fragment promoting cIAP1 depletion and caspase-8 activation.
• cIAP1 is a key downstream mediator of PAR-4's function in apoptosis.
• Combining Smac mimetics with genotoxic drugs induces synthetic lethality in PAR-4-deficient TNBC, offering a promising therapeutic approach.